At the 61st ASH Annual Meeting & Exposition, Agne Paner, Rush University Medical Center, discusses her presentation: Myeloma: Therapy, excluding Transplantation: New Approaches in the Treatment of Relapsed/Refractory Plasma Cell Dyscrasias.
1. What are the major unmet needs in the treatment of relapsed/refractory multiple myeloma? (0:05)
2. What were the findings of the HORIZON study? (0:28)
3. What progress has been made in identifying biomarkers of response to Melflufen plus Dexamethasone in relapsed/refractory multiple myeloma? (1:37)
4. What combination therapies are being investigated for relapsed/refractory multiple myeloma? (1:53)
5. How does this treatment differ from other treatment options? (2:42)
Agne Paner has received consulting honoraria for advisory board from Oncopeptides.
Filmed at the 61st ASH Annual Meeting & Exposition 2019, Orlando, FL, USA.
Share this Video
Related Videos In Haematological Malignancies
Michael Mauro, ASH 2021: 48-Week Update of the Phase III ASCEMBL Trial
Professor Michael Mauro (Memorial Sloan Kettering Cancer Center, New York City, NY, USA) discusses the 48-week update from the ASCEMBL trial, a multicenter, open-label, phase III study of the efficacy and safety of asciminib, a first-in-class STAMP inhibitor, vs Bosutinib in patients with chronic myeloid leukemia in chronic phase after ≥2 prior tyrosine kinase inhibitors: […]
Robin Foà: Dasatinib–Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults
touchONCOLOGY editorial board member Professor Robin Foà (Sapienza University of Rome, Italy) discusses his recent phase II study exploring the benefits, efficacy and safety of tyrosine kinase inhibitors dasatinib–blinatumomab for the treatment of Ph-positive acute lymphoblastic leukemia in adults. Questions What is the rationale for the use of dasatinib plus glucocorticoids, followed by blinatumomab, rather […]
Pinkal Desai, ASH 2021: Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection
We were delighted to catch up with Dr Pinkal Desai (Weill Cornell Medical College, New York City, NY, USA) to discuss the report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub on clinical predictors of outcome in adult patients with acute leukemias and myelodysplastic syndrome and COVID-19 infection. Questions 1. Prior […]
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!